Moon­Lake’s im­munol­o­gy drug gets help of in­vest­ment bankers for po­ten­tial sale — Reuters re­port

Moon­Lake Im­munother­a­peu­tics is work­ing with an in­vest­ment bank to ex­plore a po­ten­tial sale, per a Fri­day evening re­port in Reuters, cit­ing an undis­closed num­ber of un­named sources.

A sale of the pub­lic biotech would mark an­oth­er deal in the bustling in­flam­ma­tion and im­munol­o­gy R&D space, with Mer­ck’s near­ly $11 bil­lion Prometheus buy and Roche’s re­port­ed­ly $7 bil­lion pur­suit of Roivant and Pfiz­er’s bow­el dis­ease drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER